What Is BPC-157?

If you have searched “what is BPC-157,” you have probably already run into a wall of confident, contradictory claims — that it is a natural gut hormone, a miracle healing injection, a banned substance, or a newly legal prescription. This page strips that back to what is actually known and what is genuinely uncertain. It is the orientation page: what the molecule is, where it came from, why it is studied, and what its current US standing actually is. The deeper questions — whether it works, what it costs, how access works, how it compares to TB-500 — each have their own page, linked throughout.

What BPC-157 actually is

BPC-157 is a synthetic peptide — a short chain of amino acids made in a laboratory. Specifically, it is a pentadecapeptide, meaning it is exactly 15 amino acids long. Its sequence is usually written as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

The name is descriptive rather than chemical. “BPC” stands for Body Protection Compound, a larger protective protein that researchers identified in human gastric juice. The “157” refers to the position of this particular 15-amino-acid fragment within that parent protein’s sequence. You may also see BPC-157 referred to by older research names such as PL 14736, PL10, or Bepecin — these are the same compound under labels used in earlier development work.

That is the whole of the literal answer: BPC-157 is a defined, short, lab-synthesized peptide fragment. Everything else people attach to it — the healing claims, the legal debates, the controversy — is built on top of that simple structural fact.

Note: Being a “peptide” is not exotic. Insulin, oxytocin, and many medications are peptides. What makes BPC-157 unusual is not its chemistry but how little of its reputation rests on human clinical data, and how unsettled its legal status is.

Is BPC-157 a natural body compound?

This is the single most common point of confusion, and it matters, so it gets its own section.

You will frequently read that BPC-157 is “natural” or “found in your stomach.” That is only half-true, and the misleading half is doing a lot of marketing work. The parent Body Protection Compound protein does appear to occur naturally in human gastric juice. But the specific 15-amino-acid BPC-157 fragment, as it is studied and sold, does not circulate in the body as a free-standing molecule. It is a sequence that scientists isolated from the larger protein and then chemically synthesized in a lab. The vials people refer to are manufactured peptide, not something extracted from a stomach.

Two further details puncture the “natural hormone” framing:

• No confirmed endogenous receptor. Unlike a true hormone, BPC-157 does not have a single, identified human receptor that it is known to act through. Its proposed effects in animal studies are attributed to several overlapping signaling pathways rather than one clean lock-and-key mechanism.
• “Stable in gastric juice” is a property, not a pedigree. Part of why early researchers found it interesting is that it appeared unusually stable in the harsh acidic environment of the stomach — which is what made oral and other delivery routes worth studying. Stability is a useful trait; it is not evidence that the molecule is a normal part of your physiology.

The honest summary: BPC-157 is derived from a natural sequence but is itself a synthetic research compound.

Where BPC-157 came from

BPC-157 is not new. It was first described in the early 1990s by a research group led by Predrag Sikirić and Sven Seiwerth at the University of Zagreb in Croatia, beginning with reports around 1993–1994. Their starting point was a biological observation: a protein in gastric juice appeared to protect the stomach lining, and sequencing work identified the 15-amino-acid fragment that seemed to retain much of that protective (“cytoprotective”) activity.

From there, the same lab and a handful of collaborators produced the bulk of the literature over the following three decades. This origin story explains two things you will notice elsewhere on the internet. First, why BPC-157 is so often described in glowing, almost universal terms — much of the foundational work comes from a small, enthusiastic research lineage. Second, why the human evidence is thin despite hundreds of papers: the research program has been overwhelmingly preclinical, meaning conducted in animals and cell models rather than in large human trials.

Why researchers study it

In animal and laboratory models, BPC-157 has been reported to influence several biological pathways involved in healing and blood-vessel formation. At a high level, the proposed mechanisms most often cited include:

• Angiogenesis — the formation of new blood vessels, linked in studies to the VEGF / VEGFR2 pathway. New blood supply is central to repairing poorly-vascularized tissues like tendons.
• Nitric oxide (NO) signaling — involvement in the NO system, which affects blood flow and vascular tone.
• Growth and repair signaling — effects on pathways such as ERK1/2 and EGR-1 that are tied to cell migration, fibroblast activity, and tissue scaffolding.
• Anti-inflammatory and cytoprotective effects — broad tissue-protective activity across many organ systems in animal studies.

This breadth is exactly why BPC-157 attracts so many different claims — gut, tendon, muscle, nerve, liver, cardiovascular. A compound that nudges angiogenesis and inflammation could plausibly touch many tissues. But plausibility in a mechanism is not the same as a proven outcome in a person, and that distinction is the entire game with this molecule. We grade those individual claims, tissue by tissue and by evidence strength, on the BPC-157 benefits page rather than here.

What the evidence actually looks like

If you remember one thing about the research, make it this: the BPC-157 evidence base is deep in animals and shallow in humans.

There are well over a hundred preclinical studies, the vast majority in rodents, reporting tissue-protective and regenerative effects. That is a real and substantial body of work. But it sits on the preclinical side of the line that separates “interesting in mice” from “proven in people.” Human data is sparse — a small number of early-stage and pilot studies, not the large, controlled, repeated trials that establish a treatment. There is no broad regulatory approval built on that record for any BPC-157 indication.

This is not a knock so much as an accurate weather report. Many compounds look promising in animals and never replicate in humans; some do. BPC-157 is currently in the unresolved zone. Anyone presenting it as a settled, proven therapy is getting ahead of the published science. For the detailed, claim-by-claim breakdown of what is strongest (musculoskeletal), what fits its origins (gut), and what is more speculative (nerve, systemic), see what the research actually shows.

Its US legal status in 2026

This is the part that changed recently and is most often reported incorrectly, so here is the careful version, current as of this page’s update date.

BPC-157 is not an FDA-approved drug. No product is approved for sale under that name for any medical use.

Separately from approval, there is the question of compounding — whether a licensed pharmacy may prepare it from bulk ingredients on a prescription. In 2023 the FDA placed BPC-157 in Category 2, effectively barring it from compounding while safety questions were reviewed. In April 2026, the FDA removed BPC-157 from Category 2 (the removal took effect later that month). That move was widely — and wrongly — reported as “BPC-157 is now legal again.”

Here is what removal from Category 2 actually means and does not mean:

• It is not the same as being placed in Category 1 (the list of substances pharmacies may compound with a prescription). Removal from one list does not auto-promote it to the other.
• BPC-157 is scheduled for an advisory review by the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026. That committee’s vote is advisory only.
• Even a favorable PCAC vote does not make BPC-157 legally compoundable on its own. The FDA must still complete formal rulemaking — a proposed rule, a public comment period, and a final rule — before it could be added to the 503A bulk list. That process takes time; a realistic result is unlikely before late 2026 at the earliest, and the outcome is not guaranteed.

So in mid-2026, BPC-157 sits in a genuine gap: out of the “do not compound” bucket, but not yet cleared for legal compounding. Meanwhile, the vials marketed online “for research use only” (RUO) are sold for laboratory work and are explicitly not a legitimate route for personal use — they are unapproved products of unverified content. BPC-157 also remains banned in sport under the World Anti-Doping Agency’s S0 category, regardless of any compounding change.

Because this is the fast-moving part, we keep the full regulatory deep-dive on the 2026 FDA peptide reclassification page, and the broader question of peptide legality on the are peptides legal in the US? pillar. Treat any status statement, including this one, as accurate to its date and subject to change.

Where to go from here

This page answered what BPC-157 is. The natural next questions each have a dedicated page:

• Does it work, and for what? → What the research actually shows
• How does it compare to the other “healing peptide”? → BPC-157 vs TB-500
• Is it safe? → BPC-157 side effects and safety
• How do people access it legally, and what does it cost? → How to get BPC-157 and BPC-157 cost

The throughline across all of them is the same honest frame established here: BPC-157 is a real, well-defined synthetic peptide with a large animal-research literature, a thin human one, and a US legal status that — as of 2026 — is still being decided.